Codexis management's conference chat will stream live online Dec. 2
Codexis (CDXS) announced its participation in the Piper Sandler 38th Annual Healthcare Conference, scheduled for December 1-3, 2026, in New York City. Management will host a fireside chat on December 2 at 3:00 p.m. ET, which will be available via live webcast and a 90-day replay on the company’s investor relations website. The company aims to highlight its enzymatic solutions for therapeutics manufacturing, including its ECO Synthesis® Manufacturing Platform.
Codexis to Participate in Piper Sandler 38th Annual Healthcare Conference
Codexis, Inc. announced its participation in the Piper Sandler 38th Annual Healthcare Conference, scheduled for December 1-3, 2026, in New York. Management will hold a fireside chat on December 2, 2026, at 3:00 pm ET, with a live webcast available on the company's Investor Relations website. Codexis is a leading provider of enzymatic solutions for therapeutics manufacturing, developing its ECO Synthesis Manufacturing Platform and supplying high-performance enzymes through its BioCatalysis business.
Codexis (CDXS) CEO Alison Moore sold 10,651 shares solely to cover withholding on vested stock awards.
Codexis (CDXS) President and CEO Alison Moore sold 10,651 shares of common stock at $1.1371 per share on November 16, 2026. This transaction was executed solely to cover tax withholding obligations related to the vesting of her Restricted Stock Units (RSUs). Following the sale, Moore directly held 233,520 shares, which includes 91,248 RSUs.
Codexis Inc (4QK.MU) Seasonal returns chart
This article presents a seasonal returns chart for Codexis Inc (4QK.MU), displaying the average monthly price return between 2016 and 2026. The information is provided by Yahoo Finance and includes current stock data and related market trends.
Stephens & Co. maintains Codexis at Overweight, keeps price target at $5
Stephens & Co. has maintained an "Overweight" rating for Codexis (CDXS) and kept its price target at $5. This price target suggests a potential upside of 331.0% from the stock's closing price of $1.16 on November 13. Investors can find more detailed analyst ratings and price target data for Codexis on the Forecasts tab and track past and future recommendations in the News Flow section.
Weekly Recap: Codexis secures loan facility and advances ECO Synthesis
Codexis, Inc. (NASDAQ:CDXS) recently secured a loan facility of up to $60 million, drawing $42.5 million to refinance existing debt, with the loan maturing in November 2031 at a rate of at least 10.5%. The company also made significant progress in its ECO Synthesis process, producing multiple 100-gram batches with high purity and reducing cycle times by 40%, while advancing customer evaluations.
Earnings call transcript: Codexis tops Q3 2026 estimates, shares jump after hours
Codexis (CDXS) exceeded third-quarter 2026 revenue and earnings estimates, driven by strong growth in pharma biocatalysis and improved gross margins. The company highlighted significant progress in its ECO Synthesis platform for oligonucleotide manufacturing, including 100-gram scale production and new customer engagements. Despite remaining unprofitable, the positive operational trends and extended cash runway through 2028 led to a 10.64% jump in shares in after-hours trading.
Codexis Reports Third Quarter 2026 Financial Results and Provides Business Update
Codexis, Inc. reported its third-quarter 2026 financial results, with total revenues reaching $19.3 million, a significant increase from the previous year. The company reiterated its full-year revenue guidance while increasing its gross margin estimate. Key business highlights include advancements in RNA therapeutic manufacturing, a new $60 million term loan facility, and progress toward clinical-stage manufacturing agreements.
Stifel reiterates Codexis stock rating on pharma demand strength
Stifel reiterated a Buy rating and $5.00 price target on Codexis, Inc. following strong third-quarter results that surpassed consensus estimates, driven by solid pharmaceutical biocatalysis demand. Despite positive performance and new partnerships, the stock is trading near its 52-week low, appearing undervalued according to InvestingPro analysis. Stifel anticipates potential upside for Codexis in 2027, contingent on tangible commercial wins in the siRNA market.
Codexis Inc (CDXS) (Q3 2026) Earnings Call Highlights: Revenue Surges 124% as ECO Synthesis ...
Codexis Inc. reported a significant revenue increase of 124% year-over-year in Q3 2026, reaching $19.3 million, driven by growth in its biocatalysis business and progress in its ECO Synthesis platform. Despite continued net losses, the company strengthened its financial position with an equity offering and a term loan, extending its cash runway through 2028. Codexis is also seeing increased interest and engagement from biopharma and CDMO partners for its enzymatic synthesis technology, particularly concerning stereochemistry control and scalability.
What Codexis (CDXS) Said on Its Q3 Earnings Call
Codexis (CDXS) reported increased third-quarter revenue and a reduced net loss, driven by growth in its pharmaceutical biocatalysis business and progress with its ECO Synthesis platform for oligonucleotide manufacturing. The company reaffirmed its full-year revenue forecast of $72 million to $76 million and expects current cash to fund operations through 2028. Codexis is advancing its ECO Synthesis platform toward kilogram-scale production and has signed evaluation agreements with an siRNA developer and a large biopharmaceutical company.
Codexis Reports Third Quarter 2026 Financial Results and Provides Business Update
Codexis, Inc. reported third-quarter 2026 revenues of $19.3 million, reiterating its full-year revenue guidance. The company highlighted advancements in RNA therapeutic manufacturing with its ECO Synthesis® Manufacturing Platform and strengthened its balance sheet with a $60 million term loan and a $25 million equity raise. Codexis aims to advance partnerships toward clinical-stage manufacturing and plans to open its ECO GMP Manufacturing Center by the end of 2027.
Latham & Watkins Advises Codexis on US$60 Million Term Loan Facility
Latham & Watkins LLP advised Codexis, Inc. on a US$60 million senior secured term loan agreement with Trinity Capital Inc. Codexis, a provider of enzymatic solutions for therapeutics manufacturing, utilized the initial proceeds to retire existing debt. The Latham & Watkins team was led by New York partner Seniz Yakut, with significant contributions from various specialists across corporate, tax, UCC, intellectual property, data privacy, cybersecurity, and healthcare matters.
CDXS: Codexis Inc. filed SEC Form 8-K: Entry into a Material...
Codexis Inc. (CDXS) has filed an SEC Form 8-K, detailing its entry into a material definitive agreement and the termination of another. The company has secured up to $60.0M in term loans from Trinity Capital, with $42.5M funded at close, featuring interest-only payments until 2030 and maturing in 2031. This filing also includes information on the creation of a direct financial obligation, unregistered sales of equity securities, and related financial statements and exhibits.
Latham & Watkins Advises Codexis on US$60 Million Term Loan Facility
Latham & Watkins LLP advised Codexis, Inc. on a US$60 million senior secured term loan agreement with Trinity Capital Inc. The proceeds from the first tranche were used by Codexis to retire existing debt. A multidisciplinary team from Latham & Watkins, led by New York partner Seniz Yakut, represented Codexis in this debt refinancing transaction.
Codexis Enters into $60 Million Term Loan Facility with Trinity Capital
Codexis, Inc. has secured a $60 million senior secured term loan with Trinity Capital Inc., using the initial $42.5 million drawdown to refinance existing debt. This new financing provides 48 months of interest-only payments followed by a 12-month amortization, offering enhanced financial flexibility for Codexis. The company plans to use this capital to advance its growth initiatives, particularly in the siRNA therapeutic sector and the industrialization of its ECO Synthesis platform.
Codexis secures $60M term loan from Trinity Capital By Investing.com
Codexis Inc. (NASDAQ:CDXS) has secured a $60 million senior secured term loan from Trinity Capital Inc. (NYSE:TRIN). The proceeds from the first tranche were used to retire existing debt, enhancing Codexis's financial position and providing flexibility to advance growth initiatives in the siRNA therapeutic sector. The loan features 48 months of interest-only payments, followed by a 12-month amortization period beginning in November 2030.
Codexis secures $60M term loan with Trinity Capital
Codexis, Inc. has secured a $60 million senior secured term loan from Trinity Capital Inc. The proceeds from the first tranche were used to retire existing debt, and the company now has $42.5 million in total outstanding debt. This refinancing aims to enhance Codexis's financial position and provide flexibility to advance growth initiatives, particularly in the siRNA therapeutic sector.
Codexis, Inc. (0I0X.IL) latest stock news and headlines – Yahoo Finance
This Yahoo Finance page provides the latest stock news and headlines for Codexis, Inc. (0I0X.IL). It highlights recent financial activities, including a $60 million term loan facility and advancements in ECO Synthesis and siRNA manufacturing capabilities. The page also lists upcoming earnings calls and past financial results.
Codexis presents enzymatic RNA manufacturing data at TIDES Europe By Investing.com
Codexis, Inc. presented data at TIDES Europe 2026 on its ECO Synthesis Manufacturing Platform for oligonucleotide therapeutics, demonstrating product quality over 90% at a 100-gram scale with reduced cycle time. The platform also showed a 3- to 4-fold increase in potency for siRNA therapeutics compared to traditional methods and the capability to incorporate tissue-targeting moieties. This advancement aims to meet the demand for RNAi therapeutics and enhance next-generation RNA therapeutics design and performance.
Codexis reports siRNA manufacturing gains at 100-gram scale
Codexis, Inc. presented new data at TIDES Europe 2026 demonstrating significant advancements in its ECO Synthesis enzymatic RNA manufacturing platform, achieving over 90% product quality at the 100-gram scale while nearly halving cycle time. The platform also showed a 3- to 4-fold increase in siRNA potency in human hepatocyte in vitro models compared to traditional methods and now supports the incorporation of tissue-targeting moieties and phosphorothioate stereochemistry control. These developments aim to enhance the design and performance of next-generation RNA therapeutics.
Codexis Advances ECO Synthesis Toward Adoption Readiness
Codexis, Inc. presented new data at TIDES Europe 2026 showcasing the advancements of its ECO Synthesis Manufacturing Platform for oligonucleotide therapeutics. The data highlights significant gains in manufacturing efficiency, achieving over 90% product quality at 100-gram scale while nearly halving cycle time, and introduces new capabilities like efficient incorporation of tissue-targeting moieties. Additionally, the platform demonstrated a 3- to 4-fold increase in potency for siRNA therapeutics with defined phosphorothioate stereochemistry compared to traditional methods, signaling readiness for broader adoption.
Codexis, Inc. (0I0X.IL) latest press releases and corporate news
This article provides the latest press releases and corporate news for Codexis, Inc. (0I0X.IL), including announcements on third-quarter financial results and a new agreement to leverage its ECO Synthesis Manufacturing Platform. The company's stock shows a gain of 2.49% at market close.
Codexis, Inc. (0I0X.IL) Seasonal returns chart
This article from Yahoo Finance presents a seasonal returns chart for Codexis, Inc. (0I0X.IL). It shows the average monthly price return for the company between 2018 and 2026. The stock was trading at 3.7087 USD, up 2.49% at the close on July 23.
Codexis, Inc. (0I0X.IL) stock price, news, quote and history
The article provides a snapshot of Codexis, Inc. (0I0X.IL) stock performance, showing a closing price of 3.7087 USD with a 2.49% increase. It includes links to summary, news, chart, historical data, and other financial details for the company. The content also mentions that UK markets were closed at the time of the quote.
Codexis, Inc. (0I0X.IL) latest press releases and corporate news – Yahoo Finance
This page provides the latest press releases and corporate news for Codexis, Inc. (0I0X.IL), including updates on their financial results and new agreements. Recent news highlights include their upcoming third-quarter 2026 financial results report and an agreement to leverage their ECO Synthesis Manufacturing Platform. The stock was trading at 3.7087, up 2.49% at the close on July 23.
Codexis, Inc. (0I0X.IL) stock price, news, quote and history
This page provides an overview of Codexis, Inc. (0I0X.IL) stock, including its current price, performance metrics, and key financial data. The stock closed at 3.7087 USD, up 2.49%, on July 23rd. Historical data shows significant negative returns across various timeframes, with a year-to-date return of -86.42%.
Codexis, Inc. (CDXS) Seasonal Returns Chart
This article provides a seasonal returns chart for Codexis, Inc. (CDXS), showing the average monthly price return from 2016 to 2026. It includes current stock prices and after-hours trading information for CDXS. The data is presented with options to view returns over 3Y, 5Y, 10Y, 20Y, and all available years.
Codexis, Inc. (0I0X.IL) stock price, news, quote and history
This article provides a snapshot of Codexis, Inc. (0I0X.IL) stock information, showing its current price and recent performance. It also lists several recent news articles related to Codexis, including earnings reports and discussions on its manufacturing delays and biocatalysis growth. The stock was trading at 3.7087 USD, up 2.49% at the close on July 23.
Codexis Inc (4QK.MU) Seasonal returns chart - Yahoo Finance
This article from Yahoo Finance provides a seasonality chart for Codexis Inc (4QK.MU), displaying the average monthly price return from 2016 to 2026. As of the time of the article, Codexis Inc's stock was trading at 0.9630 EUR, up 0.10%. The page also shows various global market indices and cryptocurrency prices.
Codexis, Inc. (CDXS) Seasonal returns chart
This article provides a seasonal returns chart for Codexis, Inc. (CDXS), showing average monthly price returns from 2016 to 2026. The stock's current real-time price on NasdaqGS is also displayed, along with after-hours trading information.
Codexis, Inc. (0I0X.L) Seasonal returns chart
The article reports that seasonality data is currently unavailable for Codexis, Inc. (0I0X.L). It provides the stock's current price and change, noting a 4.03% decrease at market close on October 30.
Two firms report shared control of 10.8 million Codexis (CDXS) shares held for clients.
Aberdeen Group plc and abrdn Inc. have reported a shared beneficial ownership of 10,797,702 shares, representing 9.86% of Codexis (CDXS) common stock. Both firms exercise shared voting and dispositive power over these shares, which are held on behalf of their underlying clients. The disclosure was made in an amended SCHEDULE 13G/A filing with the SEC.
Codexis Inc (4QK.MU) Seasonal Returns Chart - Yahoo Finance
This Yahoo Finance article presents the seasonal returns chart for Codexis Inc (4QK.MU), showing its average monthly price return from 2016 to 2026. The stock closed at 1.0910 EUR on October 30, experiencing a -1.71% change. The page also lists related tickers and general market data for various global indices and commodities.
Codexis to Report Third Quarter 2026 Financial Results on November 12
Codexis, Inc. (NASDAQ: CDXS) announced it will report its financial results for the third quarter of 2026 on Thursday, November 12, 2026, after market close. The company's management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the results and provide a business update. The webcast will be available on the Codexis Investor Relations website, with a telephone replay available for 48 hours.
Codexis to Report Third Quarter 2026 Financial Results on November 12
Codexis, Inc. announced it will report its financial results for the third quarter of 2026 on Thursday, November 12, 2026, after market close. The company will host a conference call and webcast at 4:30 pm Eastern Time to discuss the results and provide a business update. The webcast will be available on the Codexis Investor Relations website, and a telephone replay will also be available for 48 hours.
Codexis, Inc. Estimates – BX:4QK
This page on TradingView provides financial data and analyst estimates for Codexis, Inc. (BX:4QK), a specialty chemicals company listed on BX Swiss. Users can explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. The platform emphasizes the importance of independent research, stating that the information provided is not investment advice.
Codexis Inc (4QK.DU) valuation measures and financial statistics
This article provides detailed valuation measures and financial statistics for Codexis Inc (4QK.DU), trading on the Dusseldorf exchange. It includes market capitalization, enterprise value, price-to-sales, price-to-book ratios, and various financial highlights, though many profitability and income statement figures are not available. The report also lists stock price history, share statistics, and dividend information for the company.
President and CEO Alison Moore sells $8,619 in Codexis stock
Alison Moore, President and CEO of Codexis Inc. (NASDAQ:CDXS), sold 6,335 shares of company stock for approximately $8,619 to cover tax obligations related to vested Restricted Stock Units. This transaction occurred as CDXS stock has seen a 49% decline over the past year, though InvestingPro analysis suggests it is currently undervalued. Codexis recently reported better-than-expected Q2 2026 earnings, with a narrower loss and higher revenue than analysts predicted.
Codexis Inc (4QK.DU) interactive stock chart
This page provides an interactive stock chart for Codexis Inc (4QK.DU), traded on the Dusseldorf exchange. It displays the current stock price, recent performance (+4.01%), and links to financial summaries, historical data, and recent news, including a new agreement for siRNA manufacturing and Q2 earnings reports. The market for 4QK.DU is currently open.
Codexis CFO Georgia Erbez sells $8,619 of common stock
Codexis CFO Georgia Erbez recently sold 6,335 shares of company common stock for $8,619 to cover tax obligations related to restricted stock units. Following this transaction, Erbez directly holds 60,475 shares. Despite a recent share price decline, InvestingPro analysis suggests the stock is undervalued with an upcoming earnings report on October 29.
Form 4 Codexis Inc: Georgia Erbez (Officer) For: 12 October By Investing.com
This article reports on a Form 4 filing for Codexis Inc., indicating that Georgia Erbez, an officer, made a transaction on October 12th. The article provides minimal details beyond this fact, serving primarily as an announcement of the filing.
Form 4 Codexis Inc: Georgia Erbez (Officer) For: 12 October By Investing.com
This article reports a Form 4 filing for Codexis Inc., indicating an insider transaction by officer Georgia Erbez on October 12th. The report was published on Investing.com. The content primarily consists of the filing announcement and various financial market data and news headlines from Investing.com.
Form 4 Codexis Inc: Georgia Erbez (Officer) For: 12 October By Investing.com
This article reports on a Form 4 filing for Codexis Inc., indicating that officer Georgia Erbez made a transaction on October 12th. The article is brief and primarily serves as a notification of this insider trading activity. It includes the stock symbol CDXS and notes a 5.43% increase.
Form 4 Codexis Inc: Alison Moore (Director, President and CEO) For: 12 October
This article reports on a Form 4 filing for Codexis Inc, indicating that Alison Moore, who serves as a Director, President, and CEO, had a transaction on October 12. The filing is a standard regulatory disclosure related to insider trading activities.
President and CEO Alison Moore sells $8,619 in Codexis stock By Investing.com
Alison Moore, President and CEO of Codexis Inc., sold 6,335 shares of the company's common stock for approximately $8,619 to cover tax obligations related to vested Restricted Stock Units. Despite this sale, Moore still beneficially owns 244,171 shares, including RSUs. This transaction occurred amidst a 49% drop in CDXS stock over the past year, though an InvestingPro analysis suggests the stock is currently undervalued.
Form 144 CODEXIS For: 14 October By Investing.com
This article from Investing.com is a brief announcement regarding a Form 144 filing for CODEXIS. It specifies the date as October 14 and is categorized under "Stock Market News." The article is very concise, primarily serving as a notification.
Form 144 CODEXIS, INC. Filed by: MOORE ALISON
This SEC filing is a Form 144 Notice of Proposed Sale of Securities for CODEXIS, INC., filed by Alison Moore. The filing indicates that Moore intends to sell 6,335 shares of common stock acquired through RSU vesting and settlement, with an aggregate market value of $8,619.40, on or after October 12, 2026, via Morgan Stanley Smith Barney on NASDAQ. The document provides details on the issuer, the filer's relationship to the issuer, and the specifics of the securities to be sold.
An $8.62K share sale proposed by Codexis (CDXS) officer Georgia Erbez involves a vested stock grant.
Codexis officer Georgia Erbez has filed a Form 144 proposing to sell 6,335 common shares of CDXS, with an aggregate market value of $8,619.40. These shares were acquired through RSU vesting and settlement for services rendered. The approximate sale date is listed as October 12, 2026.
Officer Alison Moore proposes selling 6,335 Codexis (Nasdaq: CDXS) shares.
Codexis officer Alison Moore has filed a notice of proposed sale for 6,335 common shares of CDXS, with an aggregate market value of $8,619.40. These shares originated from RSU vesting and settlement for services rendered, with an approximate sale date of October 12, 2026. The filing is categorized as a Form 144, indicating a proposed sale of restricted or insider-held securities.